Table 5.
Comparative analysis of BCMA CAR-T cell therapies in clinical trials.
| Items | CT103A (IASO) | Cilta-cel (legend) | Cilta-cel (legend) | CT053 (Shanghai KECHOW Pharma) | Ide-cel (BMS) |
|---|---|---|---|---|---|
| Clinical trial phase (Country) | 1b/2 (China) | 2 (China) | 1b/2 (USA) | 2 (China) | 2 (USA) |
| Number of patients enrolled | 103 (91 without prior CAR-T) | 48 | 97 | 102 | 100 |
| Dosage | 1 × 106 CAR-T cells/kg | 0.75 × 106 CAR-T cells/kg | 0.5–1.0 × 106 CAR-T cells/kg | 1.5 × 108 CAR-T cells | 300–460 × 106 CAR-T cells |
| Median follow-up time (months) | 18.07 | 26 | 18 | 20.3 | 13.3 |
| Best objective response rate (%) | 98.9 | 89.6 | 97.9 | 92.2 | 73 |
| Best CR rate (CR/sCR) (%) | 82.4 | 77.1 | 82.5 | 71.6 | 33 |
| MRD negativity rate | 97.8% | NA | NA | NA | 26% |
| Median time to response | 16 days | 0.95 month | 1 month | 29 days | 1 month |
| 12-month PFS rate | 85.5% | 77% | 77% | 76.8% | NA |
| 12-month sustained MRD negativity rate | 81.7% | NA | 53.1% | NA | 19.5% |
| Median CAR persistence time | 24-month persistence rate: 40% Median persistence duration: 419 days |
Median persistence duration: 69 days | 6-month persistence rate: undetectable in most | Median duration: 140 days | 12-month persistence rate: 36% |
| ≥Grade 3 cytokine release syndrome (%) | 1 | 35.4 | 5 | 6.9 | 5 |
| ≥Grade 3 ICANS | 0 | 0 | 5% | 0 | 3% |
BCMA: B-cell maturation antigen; CAR-T: Chimeric antigen receptor T; CR: Complete response; DoR: Duration of response; ICANS: Immune effector cell-associated neurotoxicity syndrome; NA: Not available; MM: Multiple myeloma; MRD: Minimal residual disease; ORR: Overall response rate; OS: Overall survival; PCT: Physician’s choice of treatment; PFS: Progression-free survival; RRMM: Relapsed/refractory MM; sCR: Stringent complete response.